Azienda Sanitaria Locale Roma 2
- Address
- lock Available on a paid plan
Azienda Sanitaria Locale Roma 2 - Comprehensive Clinical Research Center
Azienda Sanitaria Locale Roma 2 is a distinguished healthcare facility conducting advanced clinical research across multiple therapeutic areas. The center demonstrates particular expertise in inflammatory bowel disease, hematologic malignancies, and cardiovascular medicine, participating in pivotal international trials that advance treatment options for complex medical conditions.
- Ulcerative Colitis and inflammatory conditions, evaluating novel biologics and immunotherapies including mirikizumab, etrasimod, and efavaleukin alfa
- Hematologic malignancies including multiple myeloma, chronic myeloid leukemia, myelofibrosis, and follicular lymphoma with focus on combination therapies and treatment-free remission strategies
- Oncology research spanning triple-negative breast cancer, hormone receptor-positive breast cancer, and metastatic colorectal cancer
- Cardiovascular disease management including acute ischemic stroke, atrial fibrillation, and atherosclerotic cardiovascular disease in end-stage kidney disease patients
The center's research portfolio reflects a commitment to precision medicine and personalized treatment approaches. Their investigations encompass innovative antiplatelet strategies for cardiac interventions, biosimilar development for inflammatory conditions, and novel immunotherapy combinations for cancer treatment. With expertise in both phase II and phase III clinical trials, Azienda Sanitaria Locale Roma 2 contributes significantly to evidence-based medicine and the development of next-generation therapeutics for patients with life-threatening and chronic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 50 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 48 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1Ascentage Pharma Group Inc.2active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ascentage Pharma Group Inc.2trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale Roma 2
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants with Moderate-to-Severe Active Ulcerative Colitis. | Xencor Inc. | Phase II | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 50 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 3 | Unknown | 2021-12-01 | 2024-02-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.